Using advanced imaging and machine learning to predict breast cancer progression
Radiomics and Pathomics to predict upstaging of DCIS
['FUNDING_R01'] · H. LEE MOFFITT CANCER CTR & RES INST · NIH-11129637
This study is looking at how to better predict which patients with ductal carcinoma in situ (DCIS) might develop invasive breast cancer by using advanced imaging and technology, so that doctors can make more informed treatment choices for you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | H. LEE MOFFITT CANCER CTR & RES INST (nih funded) |
| Locations | 1 site (TAMPA, UNITED STATES) |
| Trial ID | NIH-11129637 on ClinicalTrials.gov |
What this research studies
This research focuses on ductal carcinoma in situ (DCIS) of the breast, a condition often detected through mammograms. It aims to improve the prediction of whether patients with DCIS will progress to invasive breast cancer by utilizing advanced imaging techniques and machine learning to analyze biomarkers. By identifying specific biochemical and imaging markers, the study seeks to differentiate between aggressive and indolent forms of DCIS, potentially guiding treatment decisions. Patients may undergo biopsies and imaging as part of this process.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ductal carcinoma in situ (DCIS) who are undergoing evaluation for treatment options.
Not a fit: Patients with invasive breast cancer or those without a diagnosis of DCIS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for patients with DCIS, potentially reducing unnecessary surgeries and improving outcomes.
How similar studies have performed: Other research has shown promise in using machine learning and imaging techniques to predict cancer progression, suggesting that this approach may yield valuable insights.
Where this research is happening
TAMPA, UNITED STATES
- H. LEE MOFFITT CANCER CTR & RES INST — TAMPA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NIELL, BETHANY LYNN — H. LEE MOFFITT CANCER CTR & RES INST
- Study coordinator: NIELL, BETHANY LYNN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.